HeyJaredDaniel Gilbert
- Indexed articles, last 90 days
- 3
- Latest publication
- Sep 24, 2026
- Outlet visibility, for CBS News
- Top 5K sites
- Earliest in this view
- Jul 30, 2026
Latest articles
Will an FDA crackdown curb access to cheaper GLP-1 weight-loss drugs? Here's what to know. (opens the original)
Read excerpt
The Food and Drug Administration has warned a major compounding pharmacy that it violated federal law by making copies of blockbuster weight-loss drugs in "inordinate amounts." The letter to Empower Pharmacy marks the first time the FDA has waded into a fierce debate about when a pharmacy's legitimate work of customizing a medication crosses the line into mass-copying of patented FDA-approved drugs. The FDA's warning, dated Sept. 18 but posted online Tuesday, gives Houston-based Empower an oppor
Eli Lilly takes aim at illicit market for its experimental weight-loss drug (opens the original)
Read excerpt
Eli Lilly said Wednesday it is suing six companies selling versions of its experimental weight-loss drug retatrutide, calling it the beginning of a concerted effort to crack down on a vast illicit market. That market has boomed even though retatrutide is still being studied in clinical trials and hasn't been approved by the Food and Drug Administration as safe and effective. Federal law prohibits the commercial sale of unapproved drugs, but many telehealth firms, clinics and peptide vendors onli
Judge sentences peptide vendor to nearly 6 years in prison for "an incredible trail of harm" (opens the original)
Read excerpt
SOUTH BEND, Ind. – A federal judge on Thursday sentenced the owner of a peptide company to nearly six years in prison after finding he built a massive business by deceiving customers and selling products that were adulterated with steroids. Matthew Kawa, who ran Paradigm Peptides, pleaded guilty last year to selling unapproved drugs and illegally importing them from abroad. His sentence marks a rare criminal penalty for a seller of peptides that are labeled "for research use," a largely unregula
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5K sites
For CBS News, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.